非小细胞肺癌患者化疗前后外周血中CEA、CYFRA21-1检测

目的 探讨非小细胞肺癌(NSCLC)患者化疗前后外周血中肿瘤标记物癌胚抗原(CEA)、细胞角蛋白19片断21-1(CYFRA21-1)水平的检测及其意义.方法 采用放射免疫技术对116例非小细胞肺癌患者化学治疗前后血清肿瘤标记物CEA、CYFRA21-1水平进行检测,并根据化疗前后肺部CT影像学改变进行分析.结果 CEA、CYFRA21-1水平在NSCLC化疗前后有明显变化(P＜0.05);肺癌组化疗有效者(CR PR)2种肿瘤标记物水平显著下降(P＜0.05),病情稳定(NC)和进展者(PD)二者水平无变化(P＞0.05);CEA对于肺腺癌,CYFRA21-1对于肺鳞癌化疗前效果的评定具有一定的价值.结论 检测CEA、CYFRA21-1水平有助于非小细胞肺癌化疗后疗效的判断.

Clinical Value and Combined Detection of Serum CEA and CYFRA21-1 Markers in the NSCLC Patients before and after Chemotherapy

Objective To investigate the value of combined detection of serum CEA and CYFRA21-1 markers in the patients with NSCLC before and after chemotherapy.Methods Using immunoradiometric assey,the serum CEA and CYFRA21-1 markers were measured in 116 cases of NSCLC before and after chemotherapy,while the changes of Computed Tomography(CT) images were analysed.Results After chemotherapy,the levels of CEA and CYFRA21-1 in patients with NSCLC were decreased significantly than those before chemotherapy(P<0.05).The levels of CEA and CYFRA21-1 were decreased significantly in the CR and PR patients(P<0.05),but increased or not changed in NC and PD ones(P>0.05).Before and after chemotherapy,the changes of CEA were valuable in adenocarcinoma patients,and so did CYFRA21-1 in squamous carcinoma ones.Conclusion Combined detection of serum CEA and CYFRA21-1 markers is value in monitoring and evaluating therapeutic efficacy in NSCLC patients.